Preclinical evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer. Wang Y, Situ X, Cardenas H, Siu E, et al. Clin Cancer Res 2024 Jan 17. doi: 10.1158/1078-0432.CCR-23-2368.

Read + Share

Amedeo Smart

Independent Medical Education

Wang Y, Situ X, Cardenas H, Siu E, et al. Preclinical evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer. Clin Cancer Res 2024 Jan 17. doi: 10.1158/1078-0432.CCR-23-2368.
PMID: 38231483